Ra Medical's RESULTS study to gather data over two years, Kraws says
Ra Medical (RMED) develops and commercializes excimer lasers as tools for the treatment of vascular and dermatological diseases. In an exclusive interview with The Fly, the company's President Jeffrey Kraws talked about Ra Medical's RESULTS study: "The study is named RESULTS, and that stands for revascularization rates clinical outcomes with Dabra laser long-term study. With regard to the study, we are conducting it to demonstrate that our Dabra Excimer Laser System delivers effective long-lasting results and a low re intervention rate for patients that suffer from Peripheral arterial disease. There are approximately 17.6M people we estimate in the United States that are afflicted by Peripheral arterial disease and less than 30% of them being treated today. Our study will gather data over two years post-treatment and up to 2,500 patients. Our Dabra laser system is a novel minimally invasive excimer laser photo ablation system that non thermally photochemically ablates channels and vascular blockages. Unlike many of the mechanical acoustic or thermal treatments for Peripheral arterial disease - there are competitors that may damage their arterial walls - our Dabra system treats blockages with minimal vascular trauma, and we hope to obtain results from this two years post-treatment." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.